Zealand Pharma update: partners sought and U.S. trial enrollment

Zealand Pharma is courting global commercial partners and enrolling an extra late-stage U.S. trial tied to its glepaglutide NDA, while continuing share buybacks on Nasdaq Copenhagen under its DKK 1.3bn repurchase program (treasury ~5.82% reported).